(Q33389126)

26 July 2017

title

A Phase Ib trial of CA4P (combretastatin A-4 phosphate), carboplatin, and paclitaxel in patients with advanced cancer (English)

1 reference

26 July 2017

1 reference

1 reference

G J Rustin

1

1 reference

26 July 2017

G Shreeves

2

1 reference

26 July 2017

P D Nathan

3

1 reference

26 July 2017

A Gaya

4

1 reference

26 July 2017

T S Ganesan

5

1 reference

26 July 2017

D Wang

6

1 reference

26 July 2017

J Boxall

7

1 reference

26 July 2017

L Poupard

8

1 reference

26 July 2017

D J Chaplin

9

1 reference

26 July 2017

M R L Stratford

10

1 reference

26 July 2017

J Balkissoon

11

1 reference

26 July 2017

M Zweifel

12

1 reference

26 July 2017

language of work or name

English

0 references

publication date

13 April 2010

1 reference

British Journal of Cancer

26 July 2017

published in

1 reference

26 July 2017

volume

102

1 reference

26 July 2017

issue

9

1 reference

26 July 2017

page(s)

1355-1360

1 reference

Pharmacological inhibition of the hypertensive response to combretastatin A-4 phosphate in rats

26 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2865759

Combination chemotherapy including combretastatin A4 phosphate and paclitaxel is effective against anaplastic thyroid cancer in a nude mouse xenograft model

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2865759

21 June 2018

Vascular damaging agents

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2865759

Characterizing the tumor response to treatment with combretastatin A4 phosphate

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2865759

Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2865759

Phase I trial of combretastatin a-4 phosphate with carboplatin

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2865759

Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2865759

Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2865759

Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2865759

Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic results

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2865759

Use of CA-125 to Assess Response to New Agents in Ovarian Cancer Trials

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2865759

5,6-Dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent: phase I clinical and pharmacokinetic study

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2865759

Interaction between combretastatin A-4 disodium phosphate and radiation in murine tumors

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2865759

Vascular targeting of solid tumours: a major 'inverse' volume-response relationship following combretastatin A-4 phosphate treatment of rat rhabdomyosarcomas

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2865759

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2865759

In vitro evaluation of the antineoplastic activity of combretastatin A-4, a natural product from Combretum caffrum (arid shrub).

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2865759

Assessment of pharmacodynamic vascular response in a phase I trial of combretastatin A4 phosphate

21 June 2018

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605650

Vascular targeting agents enhance chemotherapeutic agent activities in solid tumor therapy

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605650

Combretastatin A-4 phosphate enhances CPT-11 activity independently of the administration sequence

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605650

A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin a-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2865759

Combretastatin A-4 phosphate as a tumor vascular-targeting agent: early effects in tumors and normal tissues.

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2865759

Combretastatin A-1 phosphate potentiates the antitumor activity of carboplatin and paclitaxel in a severe combined immunodeficiency disease (SCID) mouse model of human ovarian carcinoma

31 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20389300

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Combination chemotherapy with combretastatin A-4 phosphate and 5-fluorouracil in an experimental murine colon adenocarcinoma

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20389300

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/SJ.BJC.6605650

1 reference

Dimensions Publication ID

26 July 2017

0 references

1 reference

26 July 2017

1 reference